Medicus Pharma Submits Phase 2 Study Design for Teverelix in Prostate Condition

Medicus Pharma (NASDAQ: MDCX) has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, targeting the prevention of recurrent acute urinary retention (AUR) in men with benign prostatic hyperplasia. The study builds on the company’s existing investigational new drug program and aims to address a significant unmet medical need.

Currently, there are no approved drug therapies specifically indicated to prevent recurrence of AUR caused by enlarged prostate. Medicus’ approach represents a novel treatment pathway in a market estimated at approximately $2 billion, positioning the company for potential expansion in men’s health therapeutics.

#MedicusPharma
#MDCX
#Biotech
#ClinicalTrials
#ProstateHealth
#BPH
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#MensHealth
#FDA
#BiotechInvesting
#LifeSciences
#NewsOut